Analysis of the molecular genetics of these MDS patients revealed that mutations in genes like RUNX1, WT1, BCOR, and TP53 were associated with typical autoinflammatory symptoms, a higher likelihood of developing AML, lower survival rates, and a worse prognosis (39). This evidence concerns the gene RUNX1 and myelodysplastic syndrome.